

# Melissa A Brown

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3750928/publications.pdf>

Version: 2024-02-01

74  
papers

5,985  
citations

116194

36  
h-index

90395

73  
g-index

76  
all docs

76  
docs citations

76  
times ranked

9926  
citing authors

#	ARTICLE	IF	CITATIONS
1	Caution: Plasmid DNA topology affects luciferase assay reproducibility and outcomes. <i>BioTechniques</i> , 2019, 67, 94-96.	0.8	5
2	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. <i>Journal of Medical Genetics</i> , 2019, 56, 347-357.	1.5	32
3	MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ breast cancer. <i>British Journal of Cancer</i> , 2019, 120, 621-632.	2.9	29
4	Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition. <i>Cancers</i> , 2018, 10, 453.	1.7	14
5	MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer. <i>Oncotarget</i> , 2018, 9, 33577-33588.	0.8	15
6	<i>BRCA1</i> and <i>BRCA2</i> 5' noncoding region variants identified in breast cancer patients alter promoter activity and protein binding. <i>Human Mutation</i> , 2018, 39, 2025-2039.	1.1	15
7	TRPC1 is a differential regulator of hypoxia-mediated events and Akt signaling in PTEN-deficient breast cancer cells. <i>Journal of Cell Science</i> , 2017, 130, 2292-2305.	1.2	69
8	Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage. <i>American Journal of Human Genetics</i> , 2017, 101, 255-266.	2.6	77
9	Long-range regulators of the lncRNA <i>HOTAIR</i> enhance its prognostic potential in breast cancer. <i>Human Molecular Genetics</i> , 2016, 25, 3269-3283.	1.4	58
10	The calcium pump plasma membrane Ca <sup>2+</sup> -ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin. <i>Scientific Reports</i> , 2016, 6, 25505.	1.6	53
11	The voltage gated Ca <sup>2+</sup> -channel Cav3.2 and therapeutic responses in breast cancer. <i>Cancer Cell International</i> , 2016, 16, 24.	1.8	34
12	Non-coding RNAs in Mammary Gland Development and Disease. <i>Advances in Experimental Medicine and Biology</i> , 2016, 886, 121-153.	0.8	25
13	No association between HPV positive breast cancer and expression of human papilloma viral transcripts. <i>Scientific Reports</i> , 2015, 5, 18081.	1.6	21
14	Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. <i>Nature Communications</i> , 2015, 6, 5899.	5.8	162
15	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	2.6	76
16	Consequences of germline variation disrupting the constitutional translational initiation codon start sites of <i>MLH1</i> and <i>BRCA2</i> : Use of potential alternative start sites and implications for predicting variant pathogenicity. <i>Molecular Carcinogenesis</i> , 2015, 54, 513-522.	1.3	14
17	Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium. <i>Human Molecular Genetics</i> , 2014, 23, 3666-3680.	1.4	96
18	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	5.8	105

#	ARTICLE	IF	CITATIONS
19	Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing. <i>Clinical Chemistry</i> , 2014, 60, 341-352.	1.5	95
20	Multifactorial Likelihood Assessment of BRCA1 and BRCA2 Missense Variants Confirms That BRCA1:c.122A>G(p.His41Arg) Is a Pathogenic Mutation. <i>PLoS ONE</i> , 2014, 9, e86836.	1.1	17
21	Long-range transcriptional regulation of breast cancer genes. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 113-125.	1.5	7
22	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. <i>American Journal of Human Genetics</i> , 2013, 92, 489-503.	2.6	201
23	BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. <i>Journal of Medical Genetics</i> , 2012, 49, 525-532.	1.5	97
24	Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. <i>Endocrine-Related Cancer</i> , 2012, 19, 509-526.	1.6	37
25	eLCR: electrochemical detection of single DNA base changes via Ligase Chain Reaction. <i>Chemical Communications</i> , 2012, 48, 12014.	2.2	38
26	Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events. <i>BMC Cancer</i> , 2012, 12, 132.	1.1	51
27	A guide for functional analysis of <i>BRCA1</i> variants of uncertain significance. <i>Human Mutation</i> , 2012, 33, 1526-1537.	1.1	117
28	Identification of fifteen novel germline variants in the <i>BRCA1</i> 3'UTR reveals a variant in a breast cancer case that introduces a functional <i>miR-103</i> target site. <i>Human Mutation</i> , 2012, 33, 1665-1675.	1.1	49
29	Expression and Function of the Protein Tyrosine Phosphatase Receptor J (PTPRJ) in Normal Mammary Epithelial Cells and Breast Tumors. <i>PLoS ONE</i> , 2012, 7, e40742.	1.1	22
30	Analysis of <i>Brca1</i> -deficient mouse mammary glands reveals reciprocal regulation of <i>Brca1</i> and <i>c-kit</i> . <i>Oncogene</i> , 2011, 30, 1597-1607.	2.6	26
31	SNORD-host RNA <i>Zfas1</i> is a regulator of mammary development and a potential marker for breast cancer. <i>Rna</i> , 2011, 17, 878-891.	1.6	321
32	Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. <i>Human Mutation</i> , 2011, 32, 678-687.	1.1	74
33	ORAI1-Mediated Calcium Influx in Lactation and in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 448-460.	1.9	188
34	p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage. <i>Cancer Research</i> , 2011, 71, 5546-5557.	0.4	72
35	Constitutional Methylation of the <i>BRCA1</i> Promoter Is Specifically Associated with <i>BRCA1</i> Mutation-Associated Pathology in Early-Onset Breast Cancer. <i>Cancer Prevention Research</i> , 2011, 4, 23-33.	0.7	147
36	Identification and functional analysis of novel BRCA1 transcripts, including mouse <i>Brca1-Iris</i> and human pseudo-BRCA1. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 239-247.	1.1	15

#	ARTICLE	IF	CITATIONS
37	Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. <i>Human Mutation</i> , 2010, 31, E1484-E1505.	1.1	86
38	Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts. <i>BMC Medical Genetics</i> , 2010, 11, 80.	2.1	25
39	Identification and Characterization of a Novel Melanoma Tumor Suppressor Gene on Human Chromosome 6q21. <i>Clinical Cancer Research</i> , 2009, 15, 797-803.	3.2	19
40	Classifying <i>MLH1</i> and <i>MSH2</i> variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. <i>Human Mutation</i> , 2009, 30, 757-770.	1.1	60
41	A novel synthetic adjuvant enhances dendritic cell function. <i>Immunology</i> , 2009, 128, e582-8.	2.0	31
42	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. <i>Nature Medicine</i> , 2009, 15, 907-913.	15.2	1,261
43	Colocalisation of predicted exonic splicing enhancers in BRCA2 with reported sequence variants. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 227-234.	1.1	15
44	Targeted disruption of <i>Brca1</i> in restricted compartments of the mouse mammary epithelia. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 237-241.	1.1	8
45	Localization of plasma membrane and secretory calcium pumps in the mammary gland. <i>Biochemical and Biophysical Research Communications</i> , 2008, 369, 977-981.	1.0	74
46	Dynamic interactions between the promoter and terminator regions of the mammalian <i>BRCA1</i> gene. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5160-5165.	3.3	127
47	Posttranscriptional Regulation of the Breast Cancer Susceptibility Gene BRCA1 by the RNA Binding Protein HuR. <i>Cancer Research</i> , 2008, 68, 9469-9478.	0.4	49
48	BRCA1 and BRCA2 Missense Variants of High and Low Clinical Significance Influence Lymphoblastoid Cell Line Post-Irradiation Gene Expression. <i>PLoS Genetics</i> , 2008, 4, e1000080.	1.5	12
49	Clinical Classification of <i>BRCA1</i> and <i>BRCA2</i> DNA Sequence Variants: The Value of Cytokeratin Profiles and Evolutionary Analysis—A Report From the kConFab Investigators. <i>Journal of Clinical Oncology</i> , 2008, 26, 1657-1663.	0.8	72
50	Pre-mRNA splicing aberrations and cancer. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 1090.	3.0	31
51	Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?. <i>Breast Cancer Research</i> , 2007, 9, R82.	2.2	58
52	Regulation of BRCA1 messenger RNA stability in human epithelial cell lines and during cell cycle progression. <i>FEBS Letters</i> , 2007, 581, 3435-3442.	1.3	9
53	Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability. <i>Breast Cancer Research and Treatment</i> , 2007, 104, 257-266.	1.1	8
54	Disruption of BRCA1 function results in telomere lengthening and increased anaphase bridge formation in immortalized cell lines. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 277-289.	1.5	37

#	ARTICLE	IF	CITATIONS
55	Genetic and Histopathologic Evaluation of BRCA1 and BRCA2 DNA Sequence Variants of Unknown Clinical Significance. <i>Cancer Research</i> , 2006, 66, 2019-2027.	0.4	153
56	Method for the generation and cultivation of functional three-dimensional mammary constructs without exogenous extracellular matrix. <i>Cell and Tissue Research</i> , 2005, 320, 207-210.	1.5	32
57	Roles of heterogeneous nuclear ribonucleoproteins A and B in cell proliferation. <i>Journal of Cell Science</i> , 2005, 118, 3173-3183.	1.2	102
58	Identification of two evolutionarily conserved and functional regulatory elements in intron 2 of the human BRCA1 gene. <i>Genomics</i> , 2005, 86, 316-328.	1.3	31
59	Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms. <i>Breast Cancer Research</i> , 2005, 7, R929-39.	2.2	24
60	Brc1 inactivation induces p27Kip1-dependent cell cycle arrest and delayed development in the mouse mammary gland. <i>Oncogene</i> , 2004, 23, 6136-6145.	2.6	18
61	MMTV-trBrca1 mice display strain-dependent abnormalities in vaginal development. <i>International Journal of Developmental Biology</i> , 2004, 48, 675-678.	0.3	5
62	Germline BRCA1 promoter deletions in UK and Australian familial breast cancer patients: Identification of a novel deletion consistent with BRCA1:BRCA1 recombination. <i>Human Mutation</i> , 2002, 19, 435-442.	1.1	32
63	Expression of a truncated Brca1 protein delays lactational mammary development in transgenic mice. <i>Transgenic Research</i> , 2002, 11, 467-478.	1.3	26
64	Gene replacement with the human BRCA1 locus: tissue specific expression and rescue of embryonic lethality in mice. <i>Oncogene</i> , 2000, 19, 4085-4090.	2.6	23
65	Identification of a C/G polymorphism in the promoter region of the BRCA1 gene and its use as a marker for rapid detection of promoter deletions. <i>British Journal of Cancer</i> , 1999, 79, 759-763.	2.9	8
66	Tumor Suppressor Genes and Human Cancer. <i>Advances in Genetics</i> , 1997, 36, 45-135.	0.8	30
67	Studies on inherited cancers: Outcomes and challenges of 25 years. <i>Trends in Genetics</i> , 1997, 13, 202-206.	2.9	18
68	Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. , 1997, 18, 102-110.		43
69	Distinct transcription start sites generate two forms of BRCA1 mRNA. <i>Human Molecular Genetics</i> , 1995, 4, 2259-2264.	1.4	99
70	Leukemia inhibitory factor (LIF) infusion stimulates skeletal muscle regeneration after injury: Injured muscle expresses lif mRNA. <i>Journal of the Neurological Sciences</i> , 1994, 123, 108-113.	0.3	124
71	Towards cloning the familial breast-ovarian cancer gene on chromosome 17. <i>Current Opinion in Genetics and Development</i> , 1994, 4, 439-445.	1.5	6
72	Alternatively spliced RNAs encode several isoforms of CD46 (MCP), a regulator of complement activation. <i>Immunogenetics</i> , 1991, 33, 335-344.	1.2	78

#	ARTICLE	IF	CITATIONS
73	Deletion mapping and expression in Escherichia coli of the large genomic segment of a birnavirus. <i>Virology</i> , 1987, 161, 145-152.	1.1	207
74	Opacity genes in <i>Neisseria gonorrhoeae</i> : Control of phase and antigenic variation. <i>Cell</i> , 1986, 47, 61-71.	13.5	470